GWM
LGND icon

Gibbs Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Gibbs Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.11M Buy
5,563
+2,215
+66% +$438K 0.15% 140
2025
Q4 		$692K Sell
3,348
-2,994
-47% -$575K 0.17% 142
2025
Q3 		$1.12M Sell
6,342
-971
-13% -$144K 0.25% 86
2025
Q2 		$831K Buy
7,313
+982
+16% +$105K 0.16% 150
2025
Q1 		$666K Buy
6,331
+1,236
+24% +$140K 0.16% 149
2024
Q4 		$546K Buy
5,095
+719
+16% +$81.3K 0.15% 150
2024
Q3 		$438K Buy
4,376
+713
+19% +$71.8K 0.14% 166
2024
Q2 		$309K Buy
+3,663
New +$291K 0.12% 181

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return

Gibbs Wealth Management's LGND Position: Q1 2026 in Review

Gibbs Wealth Management increased its Ligand Pharmaceuticals (LGND) stake by 66% in Q1 2026, buying an estimated $438K and bringing the position to 5,563 shares worth $1.11M. The position accounts for 0.15% of the portfolio, ranked #140.

Gibbs Wealth Management first reported a position in LGND in Q2 2024 and has held it in 8 quarters since. The position peaked at $1.12M in Q3 2025. 358 funds tracked by Wall St. Rank hold LGND as of Q1 2026.

  • Gibbs Wealth Management held 5,563 shares of Ligand Pharmaceuticals worth $1.11M as of Q1 2026.
  • Gibbs Wealth Management bought 2,215 Ligand Pharmaceuticals shares in Q1 2026, an estimated $438K.
  • Ligand Pharmaceuticals made up 0.15% of Gibbs Wealth Management's portfolio in Q1 2026, its #140 holding.
  • Gibbs Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2024 and has held it in 8 quarters since.
  • Gibbs Wealth Management's Ligand Pharmaceuticals position peaked at $1.12M in Q3 2025.
  • 358 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.

Based on Gibbs Wealth Management's 13F filing for Q1 2026, filed 13 May 2026.